Evidence map›Paper›PMID 42336837›Full record

ArticleNature communications2026

Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity.

Sweta Ghosh, Zachary M Vanwinkle, Sobha Rani Bodduluri, Subir Kumar Juin, Mahendar Kadari, Ankita Singh, Gerald W Dryden, Matthew B Lawrenz, Thirumala-Devi Kanneganti, Shesh N Rai and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sweta GhoshDepartment of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.ORCID 0000-0003-0613-8687
Zachary M VanwinkleDepartment of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.ORCID 0009-0005-8823-3670
Sobha Rani BodduluriDepartment of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.ORCID 0000-0002-6736-3573
Subir Kumar JuinDepartment of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.ORCID 0000-0002-9362-9937
Mahendar KadariDepartment of Microbiology and Immunology, Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY, USA.ORCID 0000-0003-4790-4202
Ankita SinghDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, USA.ORCID 0000-0002-6160-4022
Gerald W DrydenDepartment of Medicine, University of Louisville, Louisville, KY, USA.ORCID 0000-0001-9787-4537
Matthew B LawrenzDepartment of Microbiology and Immunology, Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, KY, USA.ORCID 0000-0003-1505-5429
Thirumala-Devi KannegantiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-6395-6443
Shesh N RaiBiostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cancer Data Science Center, University of Cincinnati College of Medicine, Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID 0000-0002-8377-353X
Misty GoodDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-0264-5721
Pawan KumarDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, USA.ORCID 0000-0003-3628-452X
Bodduluri HaribabuDepartment of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.ORCID 0000-0002-8261-3294
Venkatakrishna Rao JalaDepartment of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA. jvrao001@louisville.edu.ORCID 0000-0002-4206-7305

Funding

University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
AHR-NLRP6 interactions in gut barrier dysfunction and colitisR01DK135603 · NIDDK · UNIVERSITY OF LOUISVILLE · PI Venkatakrishna Rao Jala · 2024 to 2026
$1.6M
Role of urolithin A in progression of alcohol-associated liver diseaseR21AA030638 · NIAAA · UNIVERSITY OF LOUISVILLE · PI JALA, VENKATAKRISHNA RAO · 2023 to 2024
$411k
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK135603U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) P30ES030283U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P20GM125504-01U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) R21AA030638U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA191683
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AHR) plays a central role in orchestrating gut barrier and mucosal immune functions in the pathogenesis of inflammatory bowel disease (IBD). Nevertheless, activation of the AHR by diverse ligands yields varied outcomes, and the downstream pathways responsible for these effects remain unknown. Here, we report that selective activation of AHR in mouse intestinal epithelial cells (IEC) by the microbial metabolite, urolithin A (UroA), triggers the Nod-like receptor pyrin domain-containing protein 6 (NLRP6) inflammasome, resulting in the release of interleukin (IL)-18 but not IL-1β. Further, we show that UroA-induced IL-18 in IECs is critical for IL-22, mucin 2 and REG3γ production, as well as protection against colitis. Moreover, UroA significantly upregulates IL-18 and IL-22 levels in IECs and type-3 innate lymphoid cells, respectively, in intestinal biopsies from patients with IBD patients. These results demonstrate that activation of AHR by UroA modulates intestinal barrier function through an NLRP6-IL-18-IL-22 pathway in both healthy and IBD conditions.

Indexed as

CoumarinsEpithelial CellsImmunity, MucosalIntestinal MucosaReceptors, Aryl HydrocarbonAnimalsColitisFemaleHumansInflammasomesInflammatory Bowel DiseasesInterleukin-18Interleukin-22InterleukinsIntestinal Barrier FunctionMale3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneCoumarinsInflammasomesInterleukin-18Interleukin-22InterleukinsNod-like receptor pyrin domain-containing protein 6, mouseReceptors, Aryl HydrocarbonReceptors, Cell Surface

Identifiers

PMID42336837
PMCPMC13291259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.